NHS: Strike-hit appointments to be rebooked in two weeks but will impact others
Professor Meghana Pandit, NHS England's co-national medical director (secondary care), said that despite the five-day walkout by thousands of resident doctors in England, which began on Friday, local trusts have managed to maintain services with 'minimal disruption'.
She told BBC Breakfast: 'If there's any rescheduling or postponement of surgery or appointments then the hospitals try their upmost best to get that appointment rescheduled within two weeks.
'I know it is distressing and even two weeks is too long for somebody to wait and actually that has an impact on the people who who are then displaced at that two week period.'
Prof Pandit said there were three 'derogations' granted on Friday, a process which allows hospitals to request striking doctors return to work if there is a risk to patient safety.
Nottingham City Hospital reached an agreement with the British Medical Association (BMA) to exempt one doctor from the strike to work on the neonatal intensive care unit.
A derogation was agreed for one doctor in the emergency department and another doctor in the ISGM at the Northern General Hospital.
The BMA said it had also agreed a derogation for two anaesthetists to work at University Hospital Lewisham on Saturday to ensure patient safety.
It comes as Wes Streeting said 'we are doing everything we can to minimise' patient harm.
The Health Secretary condemned the strike as 'reckless' and said the Government would not allow the BMA to 'hold the country to ransom'.
Sir Keir Starmer made a last-minute appeal to resident doctors, saying the strikes would 'cause real damage'.
He added: 'Most people do not support these strikes. They know they will cause real damage…
'These strikes threaten to turn back the clock on progress we have made in rebuilding the NHS over the last year, choking off the recovery.'
The BMA has argued that real-terms pay has fallen by around 20% since 2008, and is pushing for full 'pay restoration'.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
UnitedHealth Group (UNH) Responds to the Department of Justice
UnitedHealth Group Incorporated (NYSE:UNH) is one of the top low volatility healthcare stocks to buy now. On July 24, UnitedHealth Group Incorporated (NYSE:UNH) released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'. It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.' Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'. UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.' UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.


Medscape
21 minutes ago
- Medscape
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.


Medscape
21 minutes ago
- Medscape
Cancer Care Costs High Among Privately Insured Patients
TOPLINE: A recent analysis found that privately insured US patients with newly diagnosed cancer, especially those with more advanced disease, had 'substantial out-of-pocket costs.' Monthly out-of-pocket costs among these patients increased by a mean of almost $600, on average, but increased to nearly $720 per month for those with stage IV disease. METHODOLOGY: Out-of-pocket costs for cancer care in the US are rising, but most research has focused on Medicare beneficiaries. It's important to understand privately insured patients' financial burdens, especially with cancer rates growing among younger Americans. Researchers conducted a retrospective study of 19,656 patients with cancer, using a dataset that links claims from a large private insurer to the Surveillance, Epidemiology, and End Results cancer registry. Overall, 74.1% had breast cancer, 14.5% had colorectal cancer, and 11.4% had lung cancer. Analyses also included 26,502 individuals without cancer who were assigned pseudo – diagnosis date. Monthly out-of-pocket costs (copays, co-insurance, and deductibles) were calculated from claims and inflation-adjusted to 2024 US dollars. TAKEAWAY: After a cancer diagnosis, monthly out-of-pocket costs rose by $592, on average. Those added costs increased with disease stage, from $462 per month for stage 0 cancer to $720 per month for stage IV cancer. Out-of-pocket costs spiked in the month of diagnosis and remained elevated for 6 months compared with those in individuals without cancer — totaling an average of $4145 in cumulative additional costs (over 7 months). IN PRACTICE: 'In this cohort study, patients with private insurance were found to have high OOPCs [out-of-pocket costs] after an incident diagnosis of cancer, and those with the most advanced cancer had the highest OOPCs,' the authors wrote. 'The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer.' SOURCE: This study, led by Liam Rose, PhD, Stanford University School of Medicine, Palo Alto, California, was published online in JAMA Network Open. LIMITATIONS: Differential insurance attrition could have affected the results: Patients with stage IV cancer were most likely to drop their coverage. The study could only capture direct medical costs, which misses other potential financial burdens, such as lost income and travel expenses. DISCLOSURES: This study received funding support through a grant from the American Cancer Society. One author reported receiving grants from the Department of Veterans Affairs and National Institutes of Health during the conduct of the study. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.